

**Consolidated income statement  
for the year ended 31 December 2017**

	Notes	2017 £'000	2016 £'000
<b>Revenue</b>	5	<b>100,142</b>	96,178
Cost of sales		<b>(53,097)</b>	(51,511)
<b>Gross profit</b>		<b>47,045</b>	44,667
Research and development expenses		<b>(12,318)</b>	(12,211)
Research and development expenditure credit		<b>411</b>	605
Sales and marketing expenses		<b>(7,860)</b>	(7,608)
General and administrative expenses		<b>(12,627)</b>	(6,844)
Restructuring and acquisition expenses		<b>(2,553)</b>	(1,205)
<b>Operating profit</b>		<b>12,098</b>	17,404
Investment income	9	<b>192</b>	449
<b>Profit before tax</b>		<b>12,290</b>	17,853
Tax	10	<b>(1,358)</b>	(3,052)
<b>Profit for the year attributable to shareholders</b>	7	<b>10,932</b>	14,801
<b>Earnings per share</b>			
Basic	12	<b>14.3p</b>	19.4p
Diluted	12	<b>14.0p</b>	18.9p

Dividends paid in the year amounted to £7,728,000 (2016: £7,328,000). Further disclosures are given in note 11.

All activities relate to continuing operations.

**Consolidated statement of comprehensive income  
for the year ended 31 December 2017**

	Notes	2017 £'000	2016 £'000
Profit for the year attributable to shareholders		<b>10,932</b>	14,801
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on retranslation of net investment	28/29	<b>(721)</b>	708
Tax (charge)/credit on share option and restructuring gains	10	<b>(20)</b>	434
Other comprehensive (loss)/income for the year		<b>(741)</b>	1,142
<b>Total comprehensive income for the year</b>		<b>10,191</b>	15,943